Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Cyrano Partners with Shanghai Newsummit to Develop Treatment for Loss of Smell

publication date: Oct 31, 2017

Cyrano Therapeutics of Washington DC has established a partnership with Shanghai Newsummit Biopharma for China development of theophylline, Cyrano's intranasal therapy to treat loss of smell. Newsummit will provide Cyrano, which will establish a subsidiary in China, with regulatory, clinical and market development support. Also, Newsummit helped Cyrano raise funds from a pool of private China investment firms. Newsummit is a wholly owned subsidiary of Zhejiang Yatai Pharma, an infectious disease company. More details....

Stock Symbol: (SHE: 002370)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.